Core Viewpoint - Gan Li Pharmaceutical and its European subsidiary have received a positive opinion from the CHMP for the marketing authorization applications of their rapid-acting insulin products, marking a significant advancement in their entry into the European diabetes treatment market [1][2]. Group 1: Product Development and Approval - The CHMP's positive opinion is a crucial step towards obtaining EU marketing authorization for the rapid-acting insulin products, Bysumlog® and Dazparda®, which are intended for diabetes treatment in adults and children [1]. - The CHMP recommends the approval of Bysumlog® as a biosimilar to Humalog® and Dazparda® as a biosimilar to NovoRapid®, indicating their potential to meet the needs of diabetes patients in Europe [1][2]. Group 2: Market Potential - The European diabetes treatment market presents significant clinical demand and market potential, with an estimated 65.6 million diabetes patients in Europe by 2024, representing 11.1% of the global total [2]. - The total medical expenditure related to diabetes in Europe is projected to reach $193 billion, with an average annual expenditure of $2,951 per patient, highlighting the lucrative market opportunity for the new insulin products [2]. Group 3: Competitive Landscape - The insulin market in Europe is characterized by an oligopolistic structure, with Eli Lilly dominating the market for rapid-acting insulin (Bysumlog®) and Novo Nordisk leading in the supply of Dazparda® [2]. - Eli Lilly's global sales for rapid-acting insulin are expected to reach approximately $2.325 billion in 2024, while Novo Nordisk's sales for Dazparda® are projected to be around $2.524 billion in 2025 [2]. Group 4: Investment and R&D - Gan Li Pharmaceutical has invested approximately 410 million RMB in the R&D of Bysumlog® and 212 million RMB in Dazparda® as of September 30, 2025, indicating a strong commitment to product development [3]. - Despite the positive opinion from CHMP, the company acknowledges uncertainties regarding the final approval from the EC and the commercial viability of the products in the competitive European market [3].